US Patent

US7541347 — Minocycline oral dosage forms for the treatment of acne

Method of Use · Assigned to Medicis Pharmaceutical Corp · Expires 2027-04-02 · 1y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a controlled release form of minocycline hydrochloride for the treatment of acne.

USPTO Abstract

Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.

Drugs covered by this patent

minocycline-hydrochloride (MINOCYCLINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-917`	—	minocycline-hydrochloride
`U-917`	—	minocycline-hydrochloride
`U-917`	—	minocycline-hydrochloride
`U-917`	—	minocycline-hydrochloride

Patent Metadata

Patent number: US7541347
Jurisdiction: US
Classification: Method of Use
Expires: 2027-04-02
Drug substance claim: No
Drug product claim: No
Assignee: Medicis Pharmaceutical Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.